Please assess the completion status of the following clinical trial:

Trial Title: Thymus Transplantation in DiGeorge Syndrome #668

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject's parent(s) signed the ICF.~* For a diagnosis of DiGeorge Syndrome (DGS), the subject had one of the following:~  * Heart defect~ * Hypoparathyroidism~ * 22q11 hemizygosity~ * 10p13 hemizygosity~ * Coloboma, heart defect, choanal atresia, growth and development retardation, genital hypoplasia, ear anomalies/ deafness CHARGE association mutation (CHD7 deletion);~ * PHA proliferative responses less than 20-fold above background.~* Subjects with typical Complete DiGeorge Anomaly (cDGA) had to have one of the following on 2 separate occasions:~* Circulating CD3+ T cells by flow cytometry \< 50/mm3 or PHA \< 20-fold over background~  * If CD3+ were \> 50/mm3, then CD45RA+ (cluster of differentiation 45RA) CD62L+ had to be \< 50/mm3~ * Or T cell receptor rearrangement excision circles (TRECs) by PCR had to be \< 100 per 100,000 CD3+ cells.~* Subjects with atypical cDGA had to have both of the following with 2 studies each:~  * Circulating CD3+ T cells by flow cytometry \> 500/mm3 and CD45RA+ CD62L+ CD3+ T cells \< 50/mm3 and TRECs less than 100 per 100,000 CD3+ cells.~ * T cell proliferative response to PHA more than 20-fold over background. Circulating CD3+ T cells by flow cytometry \> 500/mm3 and CD45RA+ CD62L+ CD3+ T cells \< 50/mm3 and TRECs less than 100 per 100,000 CD3+ cells.~ * T cell proliferative response to PHA more than 20-fold over background. While T cell response to PHA might have been seen, eligible subjects were to have no T cell proliferative response to antigens (less than 20-fold response) and were to have serious clinical problems related to immunodeficiency, such as opportunistic infection or failure to thrive.~Exclusion Criteria:~* Subjects on ventilators, with tracheostomies, with cytomegalovirus (CMV) infections, or requiring ongoing steroids could still be enrolled, but their data were to be analyzed separately~* Subjects who had heart surgery \< 4 weeks prior to transplant~* Heart surgery anticipated within 3 months of the proposed time of transplantation~* Ongoing parenteral steroid therapy between enrollment and transplantation~* Present or past lymphadenopathy~* Rash associated with T cell infiltration of the dermis and epidermis~* Rejection by the surgeon or anesthesiologist as surgical candidates~* Lack of sufficient muscle tissue to accept a transplant of 4 g/m2 body surface area (BSA) of the recipient~* Prior attempts at immune reconstitution, such as bone marrow transplantation or previous thymus transplantation~* Human immunodeficiency virus (HIV) infection

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cultured Thymus Tissue Implantation in Complete DiGeorge (Type: EXPERIMENTAL): Participants with Complete DiGeorge Syndrome, who were eligible, received cultured thymus tissue implantation (CTTI).~No specific dose was assigned. There was a one time administration of the cultured thymus tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).